Ricolinostat (ACY-1215)

Catalog No.S8001 Synonyms: Rocilinostat

Ricolinostat (ACY-1215) Chemical Structure

Molecular Weight(MW): 433.5

Ricolinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM in a cell-free assay. It is >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

6 Customer Reviews

  • (a) Representative images from hTERT RPE-1 cells transiently transfected with siControl (siC), treated with vehicle (DMSO), alisertib (MLN8237) or rocilinostat (ACY1215) at the time of serum withdrawal for 48 h. Ciliation monitored by immunofluorescent staining using acetylated α-tubulin (cilia marker) and pericentrin (basal body marker). Nuclei counterstained using DAPI. Highlighted boxes show magnified cilia. Scale bar, 3 μM.

    Oncogene, 2017, 36(24):3450-3463. Ricolinostat (ACY-1215) purchased from Selleck.

  • Immunoblot of MB99-1 cells treated with the indicated compound concentrations for 48 hours. Note that the HDAC6-selective inhibitors affect tubulin acetylation, but not histone H3 acetylation, whereas the pan-HDAC inhibitor TSA increases the acetylation of both.

    Mol Cancer Ther, 2015, 14(3):727-39.. Ricolinostat (ACY-1215) purchased from Selleck.

  • Western blot analysis of PARP, C-caspase-3, total MET and phosphorylated MET (p-MET) in NuDUL-1 and Toledo cells treated as metioned. GAPDH served as a loading control. NC=negative control.

    J Pathol, 2018, 246(2):141-153. Ricolinostat (ACY-1215) purchased from Selleck.

  • Effect of 9 h treatment with bortezomib (Bort, 5 nM) alone or in combination with C1A (2 µM) or ACY-1215 (ACY, 2 µM) on caspase-3/7 activity in OPM-2 cells.

    Br J Cancer, 2018, 119(10):1278-1287. Ricolinostat (ACY-1215) purchased from Selleck.

  • WB analysis of PARP and acetylated-α-tubulin in CRC cells following treatment with ACY-1215 for 24h.

    Mol Cancer Ther, 2018, 17(6):1280-1290. Ricolinostat (ACY-1215) purchased from Selleck.

  • E. The expression levels of TP and TS mRNA were evaluated by qRealTime-PCR in untreated MCF-7 cells and in MCF-7 cells that were untreated or treated with selective HDACi at the indicated concentrations for 24 hours. F. The expression of TP, TS, acetylated H3 and acetylated α-tubulin proteins was determined by western blot in untreated cells and in MCF-7 cells that were treated for 48 hours with different HDACi at the indicated concentrations. α-tubulin was used as the protein loading control

    Oncotarget, 2016, 7(7):7715-31. Ricolinostat (ACY-1215) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Ricolinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM in a cell-free assay. It is >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2. Phase 2.
Features Induced less cytotoxicity in PHA-stimulated PBMCs from 4 healthy donors compared with the pan-HDAC inhibitor SAHA.
Targets
HDAC6 [1]
(Cell-free assay)		 HDAC2 [1]
(Cell-free assay)		 HDAC3 [1]
(Cell-free assay)		 HDAC1 [1]
(Cell-free assay)		 HDAC8 [1]
(Cell-free assay)
4.7 nM 48 nM 51 nM 58 nM 100 nM
In vitro

ACY-1215 is a hydroxamic acid derivative. ACY-1215 is 12-, 10-, and 11-fold less active against HDAC1, HDAC2, and HDAC3 (class I HDACs), respectively. ACY-1215 has minimal activity (IC50 > 1μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2, and has slight activity against HDAC8 (IC50 = 0.1μM). The IC50 values for ACY-1215 for T-cell toxicity is 2.5μM. ACY-1215 overcomes tumor cell growth and survival conferred by BMSCs and cytokines in the BM milieu. ACY-1215 in combination with bortezomib induces synergistic anti-MM activity. ACY-1215 induces potent acetylation of α-tubulin at very low doses and triggers acetylation of lysine on histone H3 and histone H4 only at higher doses, confirming its specific inhibitory effect on HDAC6 activity. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RPMI8226 NUDQS3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF2NkigxtEhOzFyIH7N M2fVS|I3PDR|MEe4
A-172 NI[y[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnniNVDDqG6P MUmyOE81QCCq NHfu[4RqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MUWyOlE2ODN2MB?=
U87MG NYXzWopmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7kSXNtOTEEoH7N NX2xWlU2OjRxNEigbC=> MVXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M1PBUVI3OTVyM{Sw
Hbl-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0PEBp MUTJR|UxRTFwNjFOwG0> MnHjNlYyOTZ{N{C=
OCI-Ly10 NEXQbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;mNndnPDhiaB?= NFP4ZnNKSzVyPUCuPUDPxE1? NGm5XFczPjFzNkK3NC=>
Riva NGjCeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jGclQ5KGh? NX7sPIQ{UUN3ME2yMlIh|ryP NFHiVVQzPjFzNkK3NC=>
Su-DHL2 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZXXh4PDhiaB?= MVPJR|UxRTNwMzFOwG0> MnnnNlYyOTZ{N{C=
OCI-Ly1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr3S|c1QCCq NYi4W3J5UUN3ME2yMlQh|ryP M2rvclI3OTF4Mkew
OCI-Ly7 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;1NmgxPDhiaB?= MnHiTWM2OD1zLkKg{txO M3jGeFI3OTF4Mkew
Su-DHL4 NF2ydJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnxb|dJPDhiaB?= M1;WO2lEPTB;ND63JO69VQ>? MUKyOlEyPjJ5MB?=
Su-DHL6 M3vJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2T|Q5KGh? MkLkTWM2OD1|LkKg{txO NY\mTmRbOjZzMU[yO|A>
Hbl-2 NH[xS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLJOFghcA>? M1Poe2lEPTB;MT65JO69VQ>? M1XVZlI3OTF4Mkew
Jeko-1 NV7jVXVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTEOFghcA>? MVPJR|UxRTFwNTFOwG0> NGHBSGMzPjFzNkK3NC=>
Jvm-2 M{joVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonEOFghcA>? NYPtWo06UUN3ME20MlAh|ryP M{[1SlI3OTF4Mkew
Rec-1  NYTPbXRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj0d3R3PDhiaB?= M1WwVWlEPTB;Mj6zJO69VQ>? NWPJXVMzOjZzMU[yO|A>
CCL-119 NFrQbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq0PEBp Mm[0TWM2OD1zLkeg{txO NGLoXIszPjFzNkK3NC=>
H9 NWH6flF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvCWm81QCCq NIHkNZlKSzVyPUGuNkDPxE1? M{\GdFI3OTF4Mkew
HH MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\nc3VVPDhiaB?= MVvJR|UxRTJwNTFOwG0> MXeyOlEyPjJ5MB?=
Sup-T1 NEix[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG0PEBp NHTTeItKSzVyPUGuOkDPxE1? MkjONlYyOTZ{N{C=
MM.1S NUDOfXdCTnWwY4Tpc44hSXO|YYm= NFntfFExNTYQvF2= M3rVflYhcA>? NEjYZodqdmO{ZXHz[ZMh[WOndInsZZRm\CEQsT30eYJ2dGmw NFT5RWwzOjJ4Mke2NC=>
MM.1S MUPGeY5kfGmxbjDBd5NigQ>? NYn1cIFUOC5{NT:x{txO NGnDT2oyQCCq NH;BNYZqdmO{ZXHz[ZMh[WOndInsZZRm\CEQsT30eYJ2dGmw M{nuXlIzOjZ{N{[w
MM.1R MWXGeY5kfGmxbjDBd5NigQ>? M4rrU|AvOjVxMd88US=> M1fm[lE5KGh? M{HXZolv[3KnYYPld{Bi[2W2eXzheIVlKM7zLYT1ZpVtcW5? NHLnfXozOjJ4Mke2NC=>
RPMI8226  NH;p[3FHfW6ldHnvckBCe3OjeR?= NHPZO2MxNjJ3L{JOwG0> MmXMNVghcA>? NVLrNolWcW6lcnXhd4V{KGGlZYT5cIF1\WRizsGteJVjfWyrbh?= NEjTc3MzOjJ4Mke2NC=>
MM.1S MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV2wMVjPxE1? M{K5d|Q5KGh? NWX4PGl{\GWlcnXhd4V{KE2PLXPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVvlbIRjOjJ{NkK3OlA>
OPM1 MkjGR4VtdCCYaXHibYxqfHliQYPzZZk> M33MN|AuQM7:TR?= MVq0PEBp NHH4N4Fl\WO{ZXHz[ZMhVU1vY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF3r[GgzOjJ4Mke2NC=>
RPMI Mlu0R4VtdCCYaXHibYxqfHliQYPzZZk> M4fNS|AuQM7:TR?= MX:0PEBp M4\mRoRm[3KnYYPld{BOVS2lZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYCyNlI3Ojd4MB?=
MM.1R NGTQVmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEn4PY4xNTkQvF2= MnTiOFghcA>? NXvkNYtT\GWlcnXhd4V{KE2PLXPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3vB[lIzOjZ{N{[w
LR5 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{PFTlAuQM7:TR?= NIf4b5c1QCCq NVTkc4o4\GWlcnXhd4V{KE2PLXPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXrGTYNCOjJ{NkK3OlA>
OPM2 MnnDR4VtdCCYaXHibYxqfHliQYPzZZk> Mnn4NE05|ryP M1LXbVQ5KGh? M4C3TIRm[3KnYYPld{BOVS2lZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGHoNpMzOjJ4Mke2NC=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
Ac-α-tubulin / Ac-Histone H4 ; 

PubMed: 31015208     


Ricolinostat promotes the accumulation of acetylated (Ac) α-tubulin. MM cells were treated with the indicated concentrations of ricolinostat for 24 hours. Protein expression was measured by immunoblotting. 

Survivin / P21 / CDC2 / p53 / p-p53(S392) / Cyclin A2 / Cyclin B1; 

PubMed: 30050135     


Western blot analysis of G2/M phase cell cycle regulatory-proteins for 48 h

Bax / Bim / Bcl2 / Cleaved caspase-3 / Cleaved caspase-9 / Cleaved PARP; 

PubMed: 30050135     


Western blot analysis of apoptosis regulatory-proteins for 48 h

PI3K(p85) / AKT / p-AKT(S473) / PRAS40 / Rag C / mTOR / p-mTOR / ERK / p-ERK; 

PubMed: 30050135     


ACY-1215 treatment inhibited PI3K/AKT/mTOR and ERK signaling protein levels in ESCC EC109 and TE-1 cell lines for 48 h.

Ac-β-catenin(K49) / p-β-catenin / β-catenin; 

PubMed: 25546293     


Time-course immunoblot analysis of human NPCs treated with an HDAC6 inhibitor. Human NPCs were treated with HDAC6 inhibitor ACY-1215 at 5 μM for the times points indicated and the lysates immunoblotted with antibodies against β-catenin, Ac-Lys49-β-catenin, phos-Ser45 and phos-Ser33, Ser37, and Thr41. β-actin is using shown as loading control.

31015208 30050135 25546293
Immunofluorescence
β-tubulin / β-catenin; 

PubMed: 25546293     


Immunofluorescence staining for β-catenin treated with HDAC6 inhibitor in human NPCs. Cells were treated with 5 μM ACY-1215 or DMSO for 18 h and imaged with anti-β-catenin antibody (green), anti-β-tubulin antibody (red), and Hoechst 33342 (blue). Scale bar, 20 μm.  Quantification of β-catenin levels at the membrane represent two independent experiments with three fields of view each at 20× magnification. Error bars indicate standard deviation. ** and **** denote significance at p < 0.01 and p < 0.0001, respectively (unpaired t test).

25546293
Growth inhibition assay
Cell viability; 

PubMed: 31015208     


Ricolinostat decreases MM cell viability. A panel of MM cell lines was treated with the indicated concentrations of ricolinostat for 72 hours. Cell viability was measured by MTT assay.

31015208
In vivo ACY-1215 in combination with bortezomib triggered more significant anti-MM activity than either agent alone in suppressing tumor growth and prolonging survival in both plasmacytoma model and disseminated MM model without significant adverse effects. ACY-1215 is readily absorbed by tumor tissue. Moreover, the drug does not accumulate in tumor tissue, as evidenced by the parallel decline of acetylated α-tubulin in blood cells and tumor tissue by 24 hours after dose. [1]

Protocol

Kinase Assay:

[1]
+ Expand

HDAC enzymatic assays:

ACY-1215 is dissolved and subsequently diluted in assay buffer [50 mM HEPES, pH 7.4, 100 mM KCl, 0.001% Tween-20, 0.05% BSA, and 20 μM tris(2-carboxyethyl)phosphine] to 6-fold the final concentration. HDAC enzymes are diluted to 1.5-fold of the final concentration in assay buffer and pre-incubated with ACY-1215 for 10 minutes before the addition of the substrate. The amount of FTS (HDAC1, HDAC2, HDAC3, and HDAC6) or MAZ-1675 (HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9) used for each enzyme is equal to the Michaelis constant (Km), as determined by a titration curve. FTS or MAZ-1675 is diluted in assay buffer to 6-fold the final concentration with 0.3μM sequencing grade trypsin. The substrate/trypsin mix is added to the enzyme/compound mix and the plate is shaken for 60 seconds and then placed into a SpectraMax M5 microtiter plate reader. The enzymatic reaction is monitored for release of 7-amino-4-methoxy-coumarin over 30 minutes, after deacetylation of the lysine side chain in the peptide substrate, and the linear rate of the reaction is calculated.
Cell Research:

[1]
+ Expand
  • Cell lines: MM cell lines, patient MM cells, and PBMCs
  • Concentrations: ~8 μM
  • Incubation Time: 48 hours
  • Method:

    PBMCs from healthy donors are isolated and stimulated with 2.5 μg/mL of phytohemagglutinin (PHA) for 48 hours in the presence of increasing concentrations of ACY-1215. DNA synthesis is measured by tritiated thymidine uptake. CD4+T cells are purified from human blood with the Rosette Sep negative-selection kit. Cells are stimulated by CD3/CD28 Dynabeads for 7 days in the presence of compounds. Cell viability is assessed using alamarBlue. MM cells (2-3 × 104cells/well) are incubated in 96-well culture plates with medium and different concentrations of ACY-1215, bortezomib, and/or recombinant IL-6 (10 ng/mL) or insulin-like growth factor-1 (IGF-1; 50 ng/mL) for 24 hours at 37°C, and tritiated thymidine incorporation is measured.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: MM xenograft SCID mouse model
  • Formulation: 10% DMSO in 5% dextrose in water
  • Dosages: 50 mg/kg
  • Administration: ip
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (198.38 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 433.5
Formula

C24H27N5O3
CAS No. 1316214-52-4
Storage powder
in solvent
Synonyms Rocilinostat

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03176472 Not yet recruiting Diabetic Neuropathic Pain Regenacy Pharmaceuticals LLC October 2018 Phase 2
NCT03176472 Not yet recruiting Diabetic Neuropathic Pain Regenacy Pharmaceuticals LLC October 2018 Phase 2
NCT02856568 Withdrawn Non-Resectable Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Extrahepatic Bile Duct Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Hilar Cholangiocarcinoma|Stage IVA Extrahepatic Bile Duct Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Extrahepatic Bile Duct Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Unresectable Extrahepatic Bile Duct Carcinoma Mayo Clinic|National Cancer Institute (NCI) May 1 2017 Phase 1
NCT02856568 Withdrawn Non-Resectable Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Extrahepatic Bile Duct Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Hilar Cholangiocarcinoma|Stage IVA Extrahepatic Bile Duct Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Extrahepatic Bile Duct Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Unresectable Extrahepatic Bile Duct Carcinoma Mayo Clinic|National Cancer Institute (NCI) May 1 2017 Phase 1
NCT02661815 Active not recruiting Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma Dana-Farber Cancer Institute|Celgene Corporation June 15 2016 Phase 1
NCT02661815 Active not recruiting Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma Dana-Farber Cancer Institute|Celgene Corporation June 15 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you suggest to obtain a clear solution?

  • Answer:

    S8001 ACY-1215 can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 5 mg/ml clearly while it in 1% DMSO/30% polyethylene glycol/1% Tween 80 at 30 mg/ml is a suspension for oral administration. Please note that the precipitation will go out from the clear solution after stayed for about half an hour, So it is recommended to prepare the solution just before use.

selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products4

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

Tags: buy Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) supplier | purchase Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) cost | Ricolinostat (ACY-1215) manufacturer | order Ricolinostat (ACY-1215) | Ricolinostat (ACY-1215) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID